ロード中...
Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
Myeloproliferative neoplasms (MPN) are debilitating stem cell-derived clonal myeloid malignancies. Conventional treatments for the BCR-ABL1-negative MPN including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) have, so far, been unsatisfactory. Following the...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Bentham Science Publishers
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3480698/ https://ncbi.nlm.nih.gov/pubmed/22830345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/092986712803251511 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|